NASDAQ · PNT
POINT Biopharma Global Inc.
$12.50+$0.02 (+0.16%)
POINT Biopharma Global Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.89% below the high.
Loading market information…
NASDAQ · CTIC · USD
Stock price, earnings
Quote as of Jun 23, 2023, 07:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CTI BioPharma Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow CTI BioPharma Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 31, 2022 |
| -$0.38-35.71% vs estimate |
| $0.00 |
| Q3 2021 | Nov 12, 2021 | -$0.26-18.18% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
19 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$12.50+$0.02 (+0.16%)
POINT Biopharma Global Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.89% below the high.
$29.06$0.00 (0.0%)
CinCor Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.65% below the high.
$2.34-$0.05 (-2.09%)
EQRx, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.74% below the high.
$16.87+$0.02 (+0.12%)
VectivBio Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
$11.13+$0.03 (+0.27%)
Verve Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.41% below the high.
$9.50$0.00 (0.0%)
Poseida Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.76% below the high.
$13.48-$0.59 (-4.2%)
Crescent Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.82% below the high.
$10.25+$0.01 (+0.05%)
Gracell Biotechnologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.77% below the high.
